Nebulized Tyvaso — Total revenues
United Therapeutics Nebulized Tyvaso — Total revenues increased by 1.2% to $127.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 22.3%, from $163.80M to $127.20M. Over 3 years (FY 2021 to FY 2025), Nebulized Tyvaso — Total revenues shows relatively stable performance with a -1.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration, higher patient adoption, or expanded clinical usage of the nebulized delivery method.
Detailed definition
This metric represents the total gross sales generated from the specific nebulized formulation of the company's primary...
Peer comparison
Comparable to product-specific revenue lines in other specialty pharmaceutical companies focusing on rare disease therapies.
uthr_segment_nebulized_tyvaso_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $151.88M | $151.88M | $151.88M | $194.60M | $119.70M | $125.30M | $120.70M | $136.90M | $145.00M | $139.90M | $159.20M | $142.70M | $163.80M | $154.40M | $141.80M | $125.70M | $127.20M |
| QoQ Change | — | +0.0% | +0.0% | +28.1% | -38.5% | +4.7% | -3.7% | +13.4% | +5.9% | -3.5% | +13.8% | -10.4% | +14.8% | -5.7% | -8.2% | -11.4% | +1.2% |
| YoY Change | — | — | — | +28.1% | — | — | -38.0% | — | +21.1% | +11.7% | +31.9% | +4.2% | +13.0% | +10.4% | -10.9% | -11.9% | -22.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's nebulized tyvaso — total revenues?
- United Therapeutics (UTHR) reported nebulized tyvaso — total revenues of $127.20M in Q1 2026.
- How has United Therapeutics's nebulized tyvaso — total revenues changed year-over-year?
- United Therapeutics's nebulized tyvaso — total revenues decreased by 22.3% year-over-year, from $163.80M to $127.20M.
- What is the long-term trend for United Therapeutics's nebulized tyvaso — total revenues?
- Over 3 years (2021 to 2025), United Therapeutics's nebulized tyvaso — total revenues has grown at a -1.2% compound annual growth rate (CAGR), from $607.50M to $585.70M.
- What does nebulized tyvaso — total revenues mean?
- The total sales revenue generated specifically from the nebulized version of the company's flagship pulmonary hypertension treatment.